BAJAJHCARE — Bajaj Healthcare Income Statement
0.000.00%
- IN₹18.68bn
- IN₹20.16bn
- IN₹4.73bn
Annual income statement for Bajaj Healthcare, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
R2020 March 31st | 2021 March 31st | 2022 March 31st | R2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Interim Report | ARS | ARS | ARS | ARS |
Standards: | — | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 4,100 | 6,570 | 6,799 | 6,458 | 4,734 |
Cost of Revenue | |||||
Gross Profit | 948 | 1,929 | 1,838 | 2,630 | 2,186 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3,707 | 5,365 | 5,768 | 5,508 | 4,627 |
Operating Profit | 393 | 1,204 | 1,031 | 950 | 108 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 361 | 1,188 | 897 | 782 | -167 |
Provision for Income Taxes | |||||
Net Income After Taxes | 252 | 831 | 714 | 635 | -143 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 252 | 831 | 714 | 430 | -838 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 252 | 831 | 714 | 430 | -838 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 9.14 | 30.1 | 25.9 | 22.8 | 3.75 |
Dividends per Share | |||||
Special Dividends per Share |